Now FDA approved for cervical dystonia
DAXXIFY® is the peptide-engineered, long-lasting neurotoxin for durable symptom control injection to injection.1,2*
*Median duration of effect, defined as time from treatment until loss of ≥80% of the peak effect (change from baseline in TWSTRS total score averaged across weeks 4 and 6), was 24 weeks with DAXXIFY® 125U and 20.3 weeks with DAXXIFY® 250U. In patients that requested retreatment prior to the loss of ≥80% of peak effect, median efficacy remaining was 45% to 54% in ASPEN-1. Median time to retreatment was between 16 and 17 weeks in ASPEN-1 and cycles 1 and 2 in the ASPEN OLS.2-3
DAXXIFY® demonstrates durable symptom relief that extends beyond the current retreatment interval of 12 weeks.1,2,4-8*
Per the Phase 3 pivotal trial, DAXXIFY® is generally safe and well tolerated, with no serious treatment-related adverse events reported.1,2
*Median duration of effect, defined as time from treatment until loss of ≥80% of the peak effect (change from baseline in TWSTRS total score averaged across weeks 4 and 6), was 24 weeks with DAXXIFY® 125U and 20.3 weeks with DAXXIFY® 250U. In patients that requested retreatment prior to the loss of ≥80% of peak effect, median efficacy remaining was 45% to 54% in ASPEN-1. Median time to retreatment was between 16 and 17 weeks in ASPEN-1 and cycles 1 and 2 in the ASPEN OLS.2,3
DAXXIFY® is the only botulinum toxin engineered with cell-penetrating peptide technology.1,6-10
Proprietary peptide 3D image
Conor Gallagher, PhD
The ASPEN program
DAXXIFY® demonstrated impressive performance in the ASPEN-1 pivotal study and the ASPEN open-label study (OLS).2,3
Learn about the clinical development program.
Additional Clinical InformationAccess for physicians and patients
Revance is committed to securing broad coverage for DAXXIFY® and will provide practice support to minimize the complexity associated with reimbursement.